Michael Bloch, MD, talks about latest clinical data for PCSK9 inhibitors in lowering LDL-C and cardiovascular events, current evidence for the optimum LDL-C goals for patients with hypercholesterolemia, and...
Tom Rifai, MD, FACP, Henry Ford Health System, Regional Medical Director, Metabolic Health and Weight Management; Harvard Medical School, Online Lifestyle Medicine Course Director, Metabolic Syndrome talks...